文献速递慢性肾脏病

罗沙司他治疗非透析依赖CKD贫血的疗效与心血管安全性:三项随机临床试验汇总分析

Efficacy and Cardiovascular Safety of Roxadustat for Treatment of Anemia in Patients with Non-Dialysis-Dependent CKD: Pooled Results of Three Randomized Clinical Trials.
PubMed 文献 · Clin J Am Soc Nephrol · 2021-01-01

汇总三项3期双盲随机试验,纳入4277例非透析依赖CKD贫血患者,比较罗沙司他与安慰剂。罗沙司他显著提高第28-52周平均血红蛋白(差异1.7 g/dl),减少输血需求(HR 0.26),且主要不良心血管事件风险不劣于安慰剂。

要点

  • 罗沙司他较安慰剂显著提升非透析CKD患者血红蛋白水平。
  • 罗沙司他降低红细胞输注需求,HR为0.26。
  • 罗沙司他不增加MACE、MACE+或全因死亡风险。

核心结论

  • 罗沙司他较安慰剂更有效提高非透析依赖CKD贫血患者血红蛋白,降低输血率,且MACE风险不劣于安慰剂。

研究设计与样本

  • 三项3期双盲随机对照试验汇总分析,共纳入4277例非透析依赖CKD贫血患者,罗沙司他组2391例,安慰剂组1886例。

主要发现

  • 第28-52周平均血红蛋白较基线变化:罗沙司他组1.9 g/dl,安慰剂组0.2 g/dl,治疗差异1.7(95%CI 1.7至1.8)。
  • 前52周红细胞输注率:罗沙司他组6.1/100患者暴露年,安慰剂组20.4/100患者暴露年,HR 0.26(95%CI 0.21至0.32)。
  • MACE风险HR 1.10(95%CI 0.96至1.27),MACE+风险HR 1.07(95%CI 0.94至1.21),全因死亡风险HR 1.08(95%CI 0.93至1.26)。

临床怎么用

  • 对于非透析依赖CKD贫血患者,罗沙司他可有效提升血红蛋白并减少输血,且心血管安全性不劣于安慰剂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: We evaluated the efficacy and cardiovascular safety of roxadustat versus placebo by analyzing data pooled from three phase 3 studies of roxadustat in patients with non-dialysis-dependent CKD and CKD-related anemia. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: In the three phase 3, double-blind studies of roxadustat versus placebo evaluating the treatment of CKD-related anemia in patients not requiring dialysis, the primary efficacy end point was mean change from baseline in hemoglobin averaged over weeks 28-52, regardless of rescue therapy. The primary cardiovascular safety end point was a composite measure of major adverse cardiovascular events (MACE; all-cause mortality, myocardial infarction, stroke). MACE plus (MACE+; MACE plus unstable angina and heart failure requiring hospitalization) and all-cause mortality were key secondary safety end points. These safety end points were adjudicated. RESULTS: A total of 4277 patients with non-dialysis-dependent CKD were randomized (roxadustat, n=2391; placebo, n=1886). Baseline characteristics were comparable between groups; the mean (SD) hemoglobin was 9.1 (0.7) g/dl and mean eGFR was 20 (12) ml/min per 1.73 m2. Patients treated with roxadustat versus those treated with placebo showed a mean change from baseline in hemoglobin averaged over weeks 28-52, regardless of rescue therapy, of 1.9 versus 0.2 g/dl, a treatment difference of 1.7 (95% confidence interval [95% CI], 1.7 to 1.8). Roxadustat reduced the need for red blood cell transfusion in the first 52 weeks versus placebo (6.1 versus 20.4 per 100 patient-exposure years, respectively; hazard ratio [HR], 0.26; 95% CI, 0.21 to 0.32). There were no increased risks of MACE (HR, 1.10; 95% CI, 0.96 to 1.27), MACE+ (HR, 1.07; 95% CI, 0.94 to 1.21), all-cause mortality (HR, 1.08; 95% CI, 0.93 to 1.26), or individual MACE+ components in patients treated with roxadustat versus those treated with placebo. CONCLUSIONS: Roxadustat was more effective than placebo at increasing hemoglobin in patients with non-dialysis-dependent CKD and anemia, while decreasing transfusion rate and being noninferior to placebo with respect to risk of MACE. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: A Study of FG-4592 for the Treatment of Anemia in Chronic Kidney Disease Patients Not Receiving Dialysis, NCT01750190; Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not Requiring Dialysis (ALPS), NCT01887600; Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease (CKD), Not on Dialysis, NCT02174627.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Provenzano R, Szczech L, Leong R, et al. Efficacy and Cardiovascular Safety of Roxadustat for Treatment of Anemia in Patients with Non-Dialysis-Dependent CKD: Pooled Results of Three Randomized Clinical Trials. Clin J Am Soc Nephrol. 2021. PMID: 34362786. doi:10.2215/CJN.16191020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。